The oral Wegovy pill continues to lead the GLP-1 weight-loss medication market in the U.S. [1].
This dominance is significant as the industry shifts toward oral alternatives to injectable drugs. The ability to capture the largest market share despite new competition suggests strong brand loyalty and a high demand for non-invasive obesity treatments.
Produced by Novo Nordisk, the oral formulation of Wegovy was launched in March 2023 [4]. The medication has seen rapid adoption among patients, with prescriptions topping three million within five months of its initial launch [1]. This growth is driven by established brand recognition and a general patient preference for pills over injections [4].
Data indicates that the drug is attracting a new demographic of patients. Approximately 80% of Wegovy pill users had never taken a weight-loss medication before starting the treatment [2]. This suggests that the oral format is lowering the barrier to entry for individuals who previously avoided obesity pharmacotherapy.
However, the market landscape is evolving with the entry of Foundayo, an oral GLP-1 pill from Eli Lilly [3]. While Wegovy currently maintains its lead, some industry observers expect Foundayo to challenge this position. Reports said that the Eli Lilly product may be more accessible or cheaper, which could eventually shift the market share [1].
Despite these emerging threats, Novo Nordisk has leveraged its first-mover advantage in the oral GLP-1 space to secure a substantial user base [4]. The competition between Novo Nordisk and Eli Lilly is now centering on pricing and accessibility as both companies vie for the growing population of patients seeking oral weight-management options [1, 3].
“Oral Wegovy prescriptions topped 3 million within five months of launch”
The persistence of Wegovy's market lead indicates that early entry and brand establishment are critical in the GLP-1 sector. As Eli Lilly's Foundayo attempts to penetrate the market through potential pricing advantages, the battle for dominance will likely shift from clinical efficacy to insurance coverage and patient affordability.
